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Abstract
Background: Adherence to clinical practice guidelines for the treatment of specific illnesses may result
in unexpected outcomes, given that multiple therapies must often be given to patients with diverse medical
conditions. Yet, few studies have presented empirical evidence that quality improvement (QI) programs
both change practice by improving adherence to guidelines and improve patient outcomes under the
conditions of actual practice. Thus, we focus on patient survival, following hospitalization for acute
coronary syndrome in three successive patient cohorts from the same community hospitals, with a quality
improvement intervention occurring between cohorts two and three.
Methods: This study is a comparison of three historical cohorts of Acute Coronary Syndrome (ACS)
patients in the same five community hospitals in 1994–5, 1997, 2002–3. A quality improvement project,
the Guidelines Applied to Practice (GAP), was implemented in these hospitals in 2001.
Study participants were recruited from community hospitals located in two Michigan communities during
three separate time periods. The cohorts comprise (1) patients enrolled between December 1993 and
April 1995 (N = 814), (2) patients enrolled between February 1997 and September 1997 (N = 452), and
(3) patients enrolled between January 14, 2002 and April 13, 2003 (N = 710).
Mortality data were obtained from Michigan's Bureau of Vital Statistics for all three patient cohorts.
Predictor variables, obtained from medical record reviews, included demographic information, indicators
of disease severity (ejection fraction), co-morbid conditions, hospital treatment information concerning
most invasive procedures and the use of ace-inhibitors, beta-blockers and aspirin in the hospital and as
discharge recommendations.
Results: Adjusted in-hospital mortality showed a marked improvement with a HR = 0.16 (p < 0.001)
comparing 2003 patients in the same hospitals to those 10 years earlier. Large gains in the in-hospital
mortality were maintained based on 1-year mortality rates after hospital discharge.
Conclusion: Changes in practice patterns that follow recommended guidelines can significantly improve
care for ACS patients. In-hospital mortality gains were maintained in the year following discharge.
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Background
While clinical practice guidelines are usually developed
based on strong evidence from randomized clinical trials
(RCTs), their consistent application in clinical practice
remains challenging. RCTs are normally designed to
examine only one or two therapies at a time and often
enroll patients with fewer co-morbid conditions, who are
at overall lower risk for mortality. In the 'real world' of
clinical practice, multiple therapies must often be given all
at once and to patients, for whom the expected benefit
may be less certain, such as the elderly. Adhering to the
guidelines may therefore result in unexpected outcomes
when applied in community hospital settings. Thus, it is
important to show that quality improvement (QI) pro-
grams do not only change practice by improving adher-
ence to guidelines for hospital care [1-3], but they must
also be shown to improve patient outcomes in both short
and longer terms.
In this paper, we examine how a decade of changes and
improvement in hospital care for ACS patients have
affected both in-hospital and one-year post-hospital mor-
tality. In particular, we evaluate treatment changes and
mortality outcomes in three ACS patient cohorts observed
over 10 years in the same five community hospitals,
which, during the final cohort observations, participated
in a quality improvement (QI) program.
Methods
Design
The study compared the survival of ACS patients in three
historical cohorts enrolled at the same five community
hospitals during 1994–5, 1997, and 2002–3. A QI project,
the Guidelines Applied to Practice (GAP) project was
implemented in these hospitals in 2001 [1], one year
prior to the data collection for the latest cohort.
Setting and participants
The five community-hospitals were located in two geo-
graphically contiguous Michigan communities. These
communities have comparable patient demographics,
employment patterns, insurance coverage, proportions of
minority, unemployed and low-income residents [4-6],
and their characteristics have remained quite stable over
the 10-year period under consideration [7].
The earlier two patient cohorts were identified in the
Michigan Inter-institutional Collaborative Heart (MICH)
study [8]. This study was an ongoing assessment of ACS
practice patterns and patient outcomes in the two mid-
Michigan communities. In Phase I, 828 consenting
patients were admitted with ACS to one of the five area
hospitals between December 1993 and April 1995, with
complete record audits available for 814. Phase II enrolled
502 consenting ACS patients admitted between February
1997 and September 1997; of these, 452 had complete
medical records. While the definition of ACS is a recent
change from the earlier definition of AMI, the eligibility
criteria (positive enzymes, a working diagnosis of AMI or
ACS and symptoms) were the same for all three cohorts,
with the exception that the enzyme used was CPK-mb in
the first two cohorts and Troponin in the third. The "nor-
mal" vs. elevated cut points at each of the admitting hos-
pitals were used in all cases.
The third cohort came from the HARP study ("Heart After
Hospital Recovery Planner"), a behavioral intervention
study designed to evaluate the effectiveness of telephone
interventions to improve post-discharge cardiovascular
health behavior in patients hospitalized for ACS. This
study was conducted in the same hospitals as the MICH
studies, with patients enrolled between January 14, 2002
and April 13, 2003.
The five hospitals were also sites for the American College
of Cardiology (ACC) AMI GAP QI initiative, which took
place in 2001. Designed to improve the quality of care
according to the ACC/American Heart Association (AHA)
Practice guidelines, the GAP initiative was a multifaceted
intervention consisting of a project kick-off presentation,
creation and implementation of a customized tool kit
which included standardized: a) AMI medication and
treatment order sheets, b) clinical pathways to coordinate
in-hospital care, and c) discharge medication and referral
forms based on ACC/AHA guidelines. Details of the inter-
vention have been described elsewhere [1].
For the HARP-cum-GAP cohort, medical record audits
could be obtained from all 719 ACS patients, who con-
sented to being in the study. While patients in the HARP
study were randomized to a telephone behavioral inter-
vention after hospital discharge, mortality rates between
intervention and control groups did not differ. For the
current analysis, all 710 HARP patients with complete
records were included, after separate analyses involving
only the HARP control group subjects did not show any
difference in observed outcomes or patterns of predictors.
All three studies (MICH I, MICH II, HARP) were approved
by the University Committee on Research Involving
Human Subjects (UCRIHS) of Michigan State University
and by each of the participating Hospital Institutional
Review Boards before data were collected.
Measures
For all three cohorts, mortality information, extending to
at least one year of follow-up after the index hospitaliza-
tion, was obtained from the Michigan Bureau of Vital Sta-
tistics. Predictor variables included demographic
information, such as age (in years), gender (female vs.BMC Health Services Research 2006, 6:140 http://www.biomedcentral.com/1472-6963/6/140
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male), minority status (minority vs. non-Hispanic
whites); type of health insurance (private/commercial,
Medicare, Medicaid, none); indicators of the severity of
the disease (ejection fraction, number of diseased vessels)
and co-morbid conditions [9]; and in-hospital treatment
information concerning the invasive procedure and treat-
ments performed: Coronary Artery Bypass Graft Surgery
(CABG), Percutaneous Transluminal Angioplasty (PCI),
or Cardiac Catheterization (CATH) only. Finally, we also
obtained information on the in-hospital use of ace-inhib-
itors, beta-blockers and aspirin as well as the discharge
recommendations concerning these medications.
Analysis
Initially, we generated descriptive statistics (means, medi-
ans and percentages) to compare the three study cohorts
in terms of the demographic and clinical characteristics of
patients. Differences between the groups were assessed
using χ2 tests for categorical variables and t tests (or Wil-
coxon rank-sum tests) for continuous variables, as appro-
priate. In addition, unadjusted survival curves were
generated using Kaplan-Meier methods [10]. Survival
times were measured twice: (1) At first, we examined sur-
vival in the hospital, counting survival days from the date
of admission to the index hospital to either the date of
death or the date of discharge; (2) then we examined post
hospital survival from the day of discharge to either the
date of death or the censor date of 365 days after the index
hospital admission.
For the multivariate analysis, we employed Cox propor-
tional hazard regressions [10]. The adequacy of the pro-
portional hazard assumptions was assessed, using
graphical methods and the test by Grambsch & Thernau
based on Schoenfeld residuals [11]. The relative strength
of a variable's predictive contribution was estimated using
the chi-square difference statistic, while the models' dis-
crimination abilities were assessed using the C-statistic
[12]. All analyses were carried out with STATA 9.2 soft-
ware.
Results
The demographic characteristics of the three cohorts are
quite similar, even though contrasts reveal that the aver-
age age of patients in the HARP cohort is about 3–5 years
lower than in the MICH cohorts (Table 1). There were
greater differences with respect to the severity of illness.
Members of the HARP cohort generally appear somewhat
healthier, with fewer co-morbid conditions. They also
included relatively few patients with low (<35%) ejection
fractions, if only valid data are included: Among HARP
patients, 12.3% (out of the 612 valid responses) had low
ejection fractions, compared to 13.8% (out of 600) in
MICH 1 and 18.3% (out of 235) in MICH 2. Likewise, the
average number of diseased coronary vessels is somewhat
lower in the HARP cohort. Concerning invasive diagnostic
procedures and treatments, the main change in these five
hospitals appears to have been a substantial increase in
invasive treatments with PCI, from a low of 26.5% among
MICH 1patients to 48.2% of all patients so treated in the
most recent (HARP) cohort. Similar increases were
observed for medications administered in the hospital
and recommended upon discharge: between 1994 and
2003, the use of Angiotensin Converting Enzyme Inhibi-
tors (ACEIs) and Angiotensin Receptor Blockers (ARBs),
β-blockers and Aspirin increased substantially, both in the
hospital and after discharge. By contrast, use of thrombo-
lytic therapy fell as use of PCI increased.
Figure 1 shows the unadjusted in-hospital survival of the
ACS patients after admission. The mean hospital stay in
the HARP cohort was substantially shorter than for the
two MICH cohorts (10.7 for MICH1, 9.4 for MICH2 and
6.6 for HARP; F(2,1973) = 31.1, p < 0.01). Survival rates
were lower in the earlier MICH cohorts (Mantel-Haen-
szel's Log-rank Test: χ2 = 48.02; p < 0.001) compared to
the more recent HARP cohort, while survival differences
between the two MICH cohorts did not reach statistical
significance.
Table 2 presents the adjusted survival rates. All predictor
variables in the model meet the proportionality test for in-
hospital survival. The results indicate a substantial rise in
mortality hazards for patients with more than one co-
morbid condition – the Charlson index includes heart dis-
ease, thus all subjects in this study have one 'co-morbid-
ity', but the logarithmic shape of the fitted line implies
that the impact of additional co-morbid conditions lessens
with the presence of more co-morbid conditions. ACS
patients with ejection fractions of 45% or higher had a
mortality hazard only 38% as large as those for patients
with ejection fractions below 35% (the contrast to the 35–
44% category is also significant – p < 0.03). Invasive pro-
cedures were associated with substantial reductions in
mortality, with hazard ratios of less than 42% compared
to patients who did not undergo invasive procedures
(none of the contrasts among the three listed procedures
is significant). Among the medication categories (ACEIs
and ARBs, aspirin and thrombolytics), three show hazard
ratios whose expected magnitudes were associated with a
risk reduction in mortality of between 44 and 57% (p <
0.005).
Interaction effects between procedures and the use of
medications were generally non-significant, providing no
evidence for cumulative procedure-medication benefits.
However, the interaction between a dichotomized age var-
iable (<65 vs. 65+) and a dichotomized procedure varia-
ble (no invasive procedure vs. having an invasive
procedure) suggested that invasive procedures were moreBMC Health Services Research 2006, 6:140 http://www.biomedcentral.com/1472-6963/6/140
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beneficial among younger (<65) ACS patients. Among
younger patients, the overall mortality risk associated
with invasive procedures was only 12% of the risk among
other young patients, who did not get invasive procedures
(HR = 0.12, p < 0.001). By contrast, among older patients
the mortality risk was reduced to approximately 43% after
an invasive procedure (HR = 0.43, p < 0.001).
Figure 2 shows the unadjusted mortality risks of the ACS
patients after their discharge form the index hospital until
one year after the initial heart event. As the Log-Rank Test
confirms, survival rates differed significantly among the
three cohorts (χ2 = 17.55; p < 0.001), but post-hoc com-
parisons revealed that only the MICH 2 cohort had a sig-
nificantly lower unadjusted survival rate than the other
two cohorts.
Table 3 presents the adjusted hazard ratios. Originally, we
tested a hazard model that contained both in-hospital
medication use and discharge medications. However, due
to substantial co-linearity among the hospital and dis-
charge medications, we only retained the discharge medi-
cations in the model presented. Again, all predictor
variables in the model meet the proportionality test for
post-hospital survival. The results indicate the continued
impact of co-morbid conditions and impact of invasive
procedures on post-discharge survival. However, age is
now a predictor of mortality, with the risk of mortality
increasing by 3% for each additional year of age. Among
the discharge medications, the use of beta-blockers
reduces the post-hospital mortality risk almost by half,
while aspirin use reduces it by a third. Finally, the higher
mortality risks among MICH 2 patients disappear, after
Table 1: Patient Characteristics and Treatments in Three Cohorts (n = 1,976)
Variables: MICH1 n = 814 MICH2 n = 452 HARP n = 710 p-value
Demographics:
Age M = 63.8 M = 65.6 M = 60.7 <0.01
SD = 13.7 SD = 14.5 SD = 12.7
Gender (male) 510 (62.7%) 266 (58.9%) 443 (62.4%) >0.36
Race (white) 682 (83.8%) 364 (80.5%) 606 (85.4%) >0.09
Charlson Index M = 2.32 M = 2.69 M = 2.09 <0.01
Med = 2 Med = 2 Med = 2
Range = 1–10 Range = 1–12 Range = 1–12
Ejection Fraction <0.01
<35% 83 (10.2%) 43 (9.5%) 75 (10.4%)
35%–44% 121 (14.9%) 46 (10.2%) 115 (16.0%)
≥45% 396 (48.7%) 146 (32.3%) 422 (58.7%)
missing 214 (26.3%) 217 (48.0%) 107 (14.9%)
No. of Vessels <0.01
0 28 (3.5) 14 (3.3) 66 (11.0)
1 196 (24.6) 84 (20.0) 207 (34.3)
2 180 (22.6) 80 (19.0) 155 (25.7)
3 392 (49.2) 243 (57.7) 175 (29.0)
Invasive Procedures and Treatments:
None 200 (24.6) 142 (31.4) 72 (10.5) <0.01
CATH 614 (75.4) 312 (68.4) 638 (89.5) <0.01
PCI 216 (26.5) 136 (30.1) 342 (48.2) <0.01
CABG 185 (22.7) 74 (16.4) 158 (22.3) <0.01
Medications in Hospital:
ACEIs & ARBs 161 (19.8) 154 (34.7) 407 (57.3) <0.01
Beta-Blockers 186 (24.1) 186 (41.2) 500 (70.4) <0.01
Aspirin 498 (61.2) 307 (67.9) 614 (96.5) <0.01
Thrombolytics 480 (59.0) 278 (61.5) 77 (10.9) <0.01
Medications at Hospital Discharge:
ACEIs & ARBs 161 (19.8) 154 (34.7) 407 (57.3) <0.01
Beta-Blockers 186 (24.1) 186 (41.2) 500 (70.4) <0.01
Aspirin 498 (61.2) 307 (67.9) 614 (96.5) <0.01BMC Health Services Research 2006, 6:140 http://www.biomedcentral.com/1472-6963/6/140
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accounting for the fact that patients in this cohort had the
highest average age and were least likely to undergo inva-
sive procedures. Thus, no cohort differences in mortality
risks remain, with the largest effect attributable to differ-
ences in invasive procedures (see chi-square difference
values).
We also examined overall one-year mortality among all
patients (138 died in the hospital and 152 after discharge
from the hospital), using a Cox proportional hazard
model; but this time, the base hazard was stratified to
account for non-proportionality in the various medica-
tion groups. Again, due to co-linearity among in-hospital
and post discharge medication use, we examined two sep-
arate models with either hospital or discharge medica-
tions as predictors. (The latter proved slightly stronger
predictors of survival). Concerning the cohort compari-
son, overall one-year mortality risks were significantly
larger in the MICH 2 cohort (HR = 1.48, p < 0.001), com-
pared to the MICH 1 cohort, and were significantly
smaller in the HARP cohort (HR = 0.30, p < 0.001). In
short, the differentials in mortality risks, and especially
the improvements apparent in the HARP/GAP cohort, all
accrued during the hospital stay. After their hospital dis-
charge, patients in the more recent HARP/GAP cohort did
not experience additional incremental survival benefits,
but, at the same time, mortality gains in the hospital were
maintained at 1-year follow-up.
Discussion
During recent decades, mortality attributable to coronary
heart disease has declined, particularly among men [13].
These declines have been driven by improved early access
to emergency medical care, but also by changes in treat-
Table 2: Mortality Hazard During Stay at Index Hospital by Patient Characteristics, Treatments and Time Cohort (n = 1,972)
Variables: Hazard Ratios 95% CI p-value ∆χ2-value
Age 1.01 0.99–1.02 >0.28 1.16
Gender (male)* 0.78 0.55–1.10 >0.16 2.01
Race (white)* 1.16 0.73–1.87 >0.53 0.40
Charlson Index*** 2.03 1.43–2.88 <0.01 15.69
Ejection Fraction (<35%)* 8.71**
35%–44% 0.96 0.46–2.03 >0.92 0.01
≥45% 0.38 0.18–0.82 <0.01 6.15




CATH 0.31 0.17–0.58 <0.01 13.56
PCI 0.42 0.23–0.79 <0.01 7.21
CABG 0.19 0.08–0.47 <0.01 13.12
ACEIs & ARBs – in hospital 0.44 0.31–0.64 <0.01 18.66
Beta Blockers – in hospital 0.73 0.48–1.10 >0.13 2.31
Aspirin – in hospital 0.49 0.33–0.71 <0.01 13.87
Thrombolytics – in hospital 0.57 0.39–0.83 <0.01 8.51
Time Cohorts (MICH1)* 16.95**
MICH2 1.46 0.99–2.15 >0.05 3.57
HARP 0.16 0.05–0.46 <0.01 11.48
* Reference categories are in parentheses;
** χ2-difference value for all categories of variable;
*** Natural logarithm of Charlson Index
Model Information:
No. of In-hospital Deaths: 138; Model Likelihood Ratio χ2 (df: 16) = 282.51;
Harrel's Concordance Statistic: 0.90
Unadjusted Survival Curves Comparing Three Patient  Cohorts from the Same Hospitals during Index Hospitaliza- tion Figure 1
Unadjusted Survival Curves Comparing Three Patient 
Cohorts from the Same Hospitals during Index Hospitaliza-
tion.BMC Health Services Research 2006, 6:140 http://www.biomedcentral.com/1472-6963/6/140
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ment during hospitalization and after discharge [1,14].
Recent clinical trials testing the management of AMI and
ACS have demonstrated efficacy of invasive hospital man-
agement [15-18]. Cumulative meta-analysis of rand-
omized trials in myocardial infarction has revealed that
long-term administration of beta-blockers leads to reduc-
tions in cardiac deaths, re-infarction rates, and risks of
sudden death [19]. Similarly, benefits from the appropri-
ate use of aspirin, lipid lowering agents, and ACEIs have
been proven in multi-center, randomized, double-blind,
placebo-control trials [20-23]. Several large-scale observa-
tional studies have also demonstrated a decreased mortal-
ity from adherence to published guidelines, which
emphasize the systematic use of medications such as
ACEIs, ARBs, or β-blockers for all eligible patients follow-
ing AMI or ACS [24-26].
During the 1980s and 1990s, prior to the more recent tri-
als, practice patterns showed increased use of thrombo-
lytic therapy and PCI, and decreased use of CABG in many
geographic areas [27-31]. In the past decade, practice
guidelines have emphasized the use of Aspirin, β-blockers
and ACEIs during and after hospital discharge for ACS [1].
However, the quality of care for ACS has remained less
than optimal in many settings, and recent studies have
continued to show a lack of adherence to published
guidelines, though improvements have been noted
[1,14,32,33]. Recently, the National Study of Physician
Awareness and Adherence to Cardiovascular Disease Pre-
vention Guidelines in 2005 revealed that only 40–50% of
primary care physicians and cardiologists incorporated
guidelines into clinical practice [34].
Evaluation of changes in practice resulting from exposure
to QI interventions is complicated by the fact that mortal-
Table 3: Mortality Hazard After Discharge from Index Hospital by Patient Characteristics, Treatments and Time Cohort (n = 1,834)
Variables: Hazard Ratios 95% CI p-value ∆χ2-value
Age 1.03 1.01–1.04 <0.01 15.79
Gender (male)* 1.14 0.82–1.59 >0.45 0.57
Race (white)* 0.81 0.54–1.23 >0.32 0.98
Charlson Index*** 1.81 1.33–2.46 <0.01 14.45
Ejection Fraction (<35%)* 6.78**
35%–44% 1.59 0.89–2.83 >0.11 2.49
≥45% 0.56 0.31–1.01 >0.05 3.71




CATH 0.56 0.34–0.91 <0.02 5.45
PCI 0.29 0.16–0.53 <0.01 15.75
CABG 0.39 0.22–0.67 <0.01 11.24
ACEIs & ARBs – discharge 1.06 0.75–1.48 >0.75 0.10
Beta Blockers – discharge 0.54 0.36–0.81 <0.01 8.78
Aspirin – discharge 0.79 0.56–1.10 >0.15 1.99
Time Cohorts (MICH1)* 1.67**
MICH2 1.29 0.87–1.92 >0.21 1.56
HARP 1.19 0.77–1.85 >0.43 0.62
* Reference categories are in parentheses;
** χ2-difference value for all categories of variable;
*** Natural logarithm of Charlson Index
Model Information:
No. of Post-Hospital Discharge Deaths: 152; Model Likelihood Ratio χ2 (df: 15) = 203.73;
Harrel's Concordance Statistic: 0.81
Unadjusted Survival Curves Comparing Three Patient  Cohorts from the Same Hospitals Starting with Hospital Dis- charge to One Year After Hospital Admission Figure 2
Unadjusted Survival Curves Comparing Three Patient 
Cohorts from the Same Hospitals Starting with Hospital Dis-
charge to One Year After Hospital Admission.BMC Health Services Research 2006, 6:140 http://www.biomedcentral.com/1472-6963/6/140
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ity and other outcomes vary widely depending on
patients' risk profile [35]. Clinical characteristics, such as
co-morbid conditions and ejection fraction, substantially
influence post-AMI and ACS survival. While some clini-
cians are reluctant to treat frail patients aggressively, inva-
sive procedures for sicker patients with more co-morbid
conditions and lower ejection fractions have often been
advocated [28,36-38]. Finally, there is substantial evi-
dence that socio-demographic characteristics such as
increased age, minority race or ethnicity, and low income/
low socio-economic status are predictors of in- and post-
hospital mortality [4,38,39].
The evidence presented here is based on the comparison
of historical cohorts. While such comparisons are, in prin-
ciple, vulnerable to changes in population characteristics
as well as changes in technology increasing the probabil-
ity of incommensurate assessments, we believe that the
current comparison sheds light on how changing practice
patterns can have large effects on clinical outcomes. Since
the comparisons were based on ACS patients presenting
in the same hospitals in communities, whose populations
remained stable over the last decade with little in- and
out-migration, and since all three patient cohorts had to
meet very similar eligibility criteria, the threat of selection
bias appears small. In addition, we controlled statistically
for demographic indicators (age, gender, race) as well as
indicators of the disease severity (ejection fractions) and
co-morbid conditions. However, we do acknowledge that
information about ST elevation was not obtained in all
cohorts and could not be used as a control variable.
Conclusion
The finding that the most recent cohort (HARP/GAP) had
substantially reduced hospital mortality is highly encour-
aging particularly in light of the fact that post-discharge
mortality benefits were maintained, even when consider-
ing that many of the sicker patients survived their hospital
stay in the later cohort. For example, 24.6% and 22.3% of
the patients with 4 or more co-morbid conditions in the
MICH 1 and MICH 2 cohorts respectively died during
their hospital stay, while only 2.4% of the patients in
HARP/GAP with 4 or more co-morbid conditions died in
the hospital. Similarly, while 14.4% (17.8%) of the MICH
1 (MICH 2) patients over 64 years of age died in the hos-
pital, that rate was cut to 0.7% among the older patients
of the HARP/GAP cohort. While progress has also been
made among the younger and healthier ACS patients, the
advances among older and sicker patients are particularly
impressive. This analysis shows that the in-hospital mor-
tality improvements were sustained in the first year post-
hospitalization, despite shortened length of stay. It
appears that a quality improvement initiative has shown
substantial improvement in survival for ACS patients
attributable to increased use of effective treatments, while
decreasing length of hospital stay.
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